Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $16.69 Analyst target: $34.33 Upside: 105.69%
Dyne Therapeutics, Inc., a muscle disease company, is a biotechnology company focused on advancing therapeutics for genetically-derived muscle diseases in the United States. The company is headquartered in Waltham, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.